Membrane permeability - measurement and prediction in drug discovery

Hit and Lead Profiling: Identification and Optimization of Drug-like Molecules

Volumn 43, Issue , 2010, Pages 117-143

  Sugano, Kiyohiko ^a   Cucurull Sanchez, Lourdes ^a   Bennett, Joanne ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Blood brain barrier (BBB); in silico prediction; Intestinal barrier; Membrane permeation; Pharmacokinetics

Indexed keywords

BLOOD-BRAIN BARRIER; DRUG DISCOVERY; IN-SILICO; INTESTINAL BARRIERS; MEMBRANE PERMEABILITY; MEMBRANE PERMEATION;

PHARMACOKINETICS;

EID: 85018193666     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527627448.ch6     Document Type: Chapter

References (112)

1. Artursson, P. and Matsson, P. (2006) Cell culture absorption models-state of the art, in Pharmacokinetic Profiling Drug Research (eds B. Testa, S. Kramer, H. Wunderli-Allenspach and G. Folkers), Wiley-VCH, Zurich, pp. 71-78.
2. Artursson, P., Neuhoff, S., Matsson, P. and Tavelin, S. (2006) Passive permeability and active transport models for, the prediction of oral absorption. Comprehensive Medicinal Chemistry II, 5, 259-278.
3. Sugano, K. (2007) Artificial membrane technologies to assess transfer and permeation of drugs in drug discovery, in Comprehensive Medicinal Chemistry II, ADME-Tox Approach, Vol. V (eds B. Testa and H. van de Waterbeemd), Elsevier, Oxford, pp. 453-487.
4. Abbott, N.J. (2006) In vitro models for examining and predicting brain uptake of drugs, in Comprehensive Medicinal Chemistry II, ADME-Tox Approach, Vol. 5. (eds B. Testa and H. van de Waterbeemd), Elsevier, Oxford, pp. 301-320.
5. Scherrmann, J.M. (2006) The biology and function of transporters, in Comprehensive Medicinal Chemistry II, ADME-Tox Approach, Vol. 5. (eds B. Testa and H. van de Waterbeemd), Elsevier, Oxford, pp. 51-85.
6. He, Y., Murby, S., Warhurst, G., Gifford, L., Walker, D., Ayrton, J., Eastmond, R. and Rowland, M. (1998) Species differences in size discrimination in the paracellular pathway refrected by oral bioavailability of poly(ethylene glycol) and D-peptides. Journal of Pharmaceutical Sciences, 87, 626-633.
7. Oliver, R.E., Jones, A.F. and Rowland, M. (1998) What surface of the intestinal epithelium is effectively available to permeating drugs? Journal of Pharmaceutical Sciences, 87, 634-639.
8. Winne, D. (1978) The permeability coefficient of the wall of a villous membrane. Journal of Mathematical Biology, 6, 95-108.
9. Fagerholm, U., Johansson, M. and Lennernaes, H. (1996) Comparison between permeability coefficients in rat and human jejunum. Pharmaceutical Research, 13, 1336-1342.
10. Chiou, W.L. (1994) Effect of ?unstirred? water layer in the intestine on the rate and extent of absorption after oral administration. Biopharmaceutics & Drug Disposition, 15, 709-717.
11. DeSesso, J.M. and Jacobson, C.F. (2001) Anatomical and physiological parameters affecting gastrointestinal absorption in humans and rats. Food and Chemical Toxicology, 39, 209-228.
12. Haruta, S., Iwasaki, N., Ogawara, K.-i., Higaki, K. and Kimura, T. (1998) Absorption behavior of orally administered drugs in rats treated with propantheline. Journal of Pharmaceutical Sciences, 87, 1081-1085.
13. Sawamoto, T., Haruta, S., Kurosaki, Y., Higaki, K. and Kimura, T. (1997) Prediction of the plasma concentration profiles of orally administered drugs in rats on the basis of gastrointestinal transit kinetics and absorbability. Journal of Pharmacy and Pharmacology, 49, 450-457.
14. Hubatsch, I., Ragnarsson, E.G.E. and Artursson, P. (2007) Determination of drug permeability and prediction of drug absorption in Caco-2. monolayers. Nature Protocols, 2, 2111-2119.
15. Hidalgo, I.J. (2001) Assessing the absorption of new pharmaceuticals. Current Topics in Medicinal Chemistry, 1, 385-401.
16. Behrens, I., Kamm,W., Dantzig, A.H. and Kissel, T. (2004) Variation of peptide transporter PepT1. and HPT1. expression in Caco-2. cells as a function of cell origin. Journal of Pharmaceutical Sciences, 93, 1743-1754.
17. Tang, F., Horie, K. and Borchardt, R.T. (2002) Are MDCK cells transfected with the human MRP2. gene a good model of the human intestinal mucosa? Pharmaceutical Research, 19, 773-779.
18. Evers, R., Kool, M., Van Deemter, L., Janssen, H., Calafat, J., Oomen, L.C.J.M., Paulusma, C.C., Elferink, R.P.J.O., Baas, F., Schinkel, A.H. and Borst, P. (1998) Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA. Journal of Clinical Investigation, 101, 1310-1319.
19. Evers, R., Cnubben, N.H.P., Wijnholds, J., van Deemter, L., van Bladeren, P.J. and Borst, P. (1997) Transport of glutathione prostaglandin A conjugates by the multidrug resistance protein 1. FEBS Letters, 419, 112-116.
20. Tang, F., Horie, K. and Borchardt, R.T. (2002) Are MDCK cells transfected with the human MDR1. gene a good model of the human intestinal mucosa? Pharmaceutical Research, 19, 765-772.
21. Benet, L.Z., Cummins, C.L. andWu, C.Y. (2004) Unmasking the dynamic interplay between efflux transporters and metabolic enzymes. International Journal of Pharmaceutics, 277, 3-9.
22. Irvine, J.D., Takahashi, L., Lockhart, K., Cheong, J., Tolan, J.W., Selick, H.E. and Grove, J.R. (1999) MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. Journal of Pharmaceutical Sciences, 88, 28-33.
23. Shah, P., Jogani, V., Bagchi, T. and Misra, A. (2006) Role of Caco-2. cell monolayers in prediction of intestinal drug absorption. Biotechnology Progress, 22, 186-198.
24. Tavelin, S., Taipalensuu, J., Hallboeoek, F., Vellonen, K.-S., Moore, V. and Artursson, P. (2003) An improved cell culture model based on 2/4/A1. cell monolayers for studies of intestinal drug transport: characterization of transport routes. Pharmaceutical Research, 20, 373-381.
25. Matsson, P., Bergstroem, C.A.S., Nagahara, N., Tavelin, S., Norinder, U. and Artursson, P. (2005) Exploring the role of different drug transport routes in permeability screening. Journal of Medicinal Chemistry, 48, 604-613.
26. Wikman, A., Karlsson, J., Carlstedt, I. and Artursson, P. (1993) A drug absorption model based on the mucus layer producing human intestinal goblet cell line HT29-H. Pharmaceutical Research, 10, 843-852.
27. Pontier, C., Pachot, J., Botham, R., Lenfant, B. and Arnaud, P. (2001) HT29-MTX and Caco-2/TC7. monolayers as predictive models for human intestinal absorption: role of the mucus layer. Journal of Pharmaceutical Sciences, 90, 1608-1619.
28. Keely, S., Rullay, A., Wilson, C., Carmichael, A., Carrington, S., Corfield, A., Haddleton, D.M. and Brayden, D.J. (2005) In vitro and ex vivo intestinal tissue models to measure mucoadhesion of poly (methacrylate) and N-trimethylated chitosan polymers. Pharmaceutical Research, 22, 38-49.
29. Gumbleton, M. and Audus, K.L. (2001) Progress and limitations in the use of in vitro cell cultures to serve as a permeability screen for the blood-brain barrier. Journal of Pharmaceutical Sciences, 90, 1681-1698.
30. Lundquist, S. and Renftel, M. (2002) The use of in vitro cell culture models for mechanistic studies and as permeability screens for the blood-brain barrier in the pharmaceutical industry-Background and current status in the drug discovery process. Vascular Pharmacology, 38, 355-364.
31. Breedveld, P., Beijnen, J.H. and Schellens, J.H.M. (2006) Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs. Trends in Pharmacological Sciences, 27, 17-24.
32. Pardridge, W.M. (2007) Drug targeting to the brain. Pharmaceutical Research, 24, 1733-1744.
33. Cecchelli, R., Dehouck, B., Descamps, L., Fenart, L., Buee-Scherrer, V., Duhem, C., Lundquist, S., Rentfel, M., Torpier, G. and Dehouck, M.P. (1999) In vitro model for evaluating drug transport across the blood-brain barrier. Advanced Drug Delivery Reviews, 36, 165-178.
34. Balimane, P.V., Han, Y.-H. and Chong, S. (2006) Current industrial practices of assessing permeability and P-glycoprotein interaction. AAPS Journal, 8, E1-E13.
35. Englund, G., Rorsman, F.,Roennblom, A., Karlbom, U., Lazorova, L., Grasjoe, J., Kindmark, A. and Artursson, P. (2006) Regional levels of drug transporters along thehumanintestinal tract:co-expressionof ABCandSLCtransportersandcomparison with Caco-2. cells. European Journal of Pharmaceutical Sciences, 29, 269-277.
36. Toyobuku, H., Tamai, I., Ueno, K. and Tsuji, A. (2003) Limited influence of P-glycoprotein on small-intestinal absorption of cilostazol, a high absorptive permeability drug. Journal of Pharmaceutical Sciences, 92, 2249-2259.
37. Lennernas, H. (2003) Intestinal drug absorption and bioavailability: Beyond involvement of single transport function. Journal of Pharmacy and Pharmacology, 55, 429-433.
38. Wang, Q., Rager, J.D., Weinstein, K., Kardos, P.S., Dobson, G.L., Li, J. and Hidalgo, I.J. (2005) Evaluation of the MDR-MDCK cell line as a permeability screen for the blood-brain barrier. International Journal of Pharmaceutics, 288, 349-359.
39. Garberg, P., Ball, M., Borg, N., Cecchelli, R., Fenart, L., Hurst, R.D., Lindmark, T., Mabondzo, A., Nilsson, J.E., Raub, T.J., Stanimirovic, D., Terasaki, T., Oeberg, J.O. and Oesterberg, T. (2005) In vitro models for the blood-brain barrier. Toxicology In Vitro: An International Journal Published in Association with BIBRA, 19, 299-334.
40. Lennernaes, H. and Abrahamsson, B. (2006) The biopharmaceutics classification system. Comprehensive Medicinal Chemistry II, 5, 971-988.
41. Feng, M.R. (2002) Assessment of blood-brain barrier penetration: In silico, in vitro and in vivo. Current Drug Metabolism, 3, 647-657.
42. Carrara, S., Reali, V., Misiano, P., Dondio, G. and Bigogno, C. (2007) Evaluation of in vitro brain penetration: Optimized PAMPA and MDCKII-MDR1. assay comparison. International Journal of Pharmaceutics, 345, 125-133.
43. Xiang, T., Xu, Y. and Anderson, B.D. (1998) The barrier domain for solute permeation varies with lipid bilayer phase structure. Journal of Membrane Biology, 165, 77-90.
44. Joguparthi,V., Xiang, T.-X. and Anderson, B.D. (2007) Liposome transport of hydrophobic drugs: gel phase lipid bilayer permeability and partitioning of the lactone form of a hydrophobic camptothecin, DB-67. Journal of Pharmaceutical Sciences, 97, 400-420.
45. Burton, P.S., Conradi, R.A. and Hilgers, A.R. (1991) Mechanisms of peptide and protein absorption. (2). Transcellular mechanism of peptide and protein, absorption: passive aspects. Advanced Drug Delivery Reviews, 7, 365-386.
46. Sugano, K., Yoshida, S., Takaku, M., Haramura, M., Saitoh, R., Nabuchi, Y. and Ushio, H. (2000) Quantitative structureintestinal permeability relationship of benzamidine analogue thrombin inhibitor. Bioorganic & Medicinal Chemistry Letters, 10, 1939-1942.
47. Kansy, M., Senner, F. and Gubernator, K. (1998) Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes. Journal of Medicinal Chemistry, 41, 1007-1010.
48. Wohnsland, F. and Faller, B. (2001) Highthroughput permeability pH profile and high-throughput alkane/water log P with artificial membranes. Journal ofMedicinal Chemistry, 44, 923-930.
49. Sugano, K., Hamada, H., Machida, M. and Ushio, H. (2001) High throuput prediction of oral absorption: Improvement of the composition of the lipid solution used in parallel artificial membrane permeation assay. Journal of Biomolecular Screening, 6, 189-196.
50. Avdeef, A., Strafford, M., Block, E., Balogh, M.P., Chambliss,W. and Khan, I. (2001) Drug absorption in vitro model: filter-immobilized artificial membranes; 2. Studies of the permeability properties of lactones in Piper methysticum Forst. European Journal of Pharmaceutical Sciences, 14, 271-280.
51. Di, L., Kerns, E.H., Fan, K., McConnell, O.J. and Carter, G.T. (2003) High throughput artificial membrane permeability assay for blood-brain barrier. European Journal of Medicinal Chemistry, 38, 223-232.
52. Galinis-Luciani, D., Nguyen, L. and Yazdanian, M. (2007) Is parallel artificial membrane permeability assay a useful tool for discovery? Journal of Pharmaceutical Sciences, 96, 2886-2892.
53. Avdeef, A., Bendels, S., Di, L., Faller, B., Kansy, M., Sugano, K. and Yamauchi, Y. (2007) Parallel artificial membrane permeability assay (PAMPA)-critical factors for better predictions of absorption. Journal of Pharmaceutical Sciences, 96, 2893-2909.
54. Sugano, K., Nabuchi, Y., Machida, M. and Asoh, Y. (2004) Permeation characteristics of a hydrophilic basic compound across a bio-mimetic artificial membrane. International Journal of Pharmaceutics, 275, 271-278.
55. Seo, P.R., Teksin, Z.S., Kao, J.P.Y. and Polli, J.E. (2006) Lipid composition effect on permeability across PAMPA. European Journal of Pharmaceutical Sciences, 29, 259-268.
56. Teksin, Z.S., Hom, K., Balakrishnan, A. and Polli, J.E. (2006) Ion pair-mediated transport of metoprolol across a three lipid-component PAMPA system. Journal of Controlled Release, 116, 50-57.
57. Flaten, G.E., Bunjes, H., Luthman, K. and Brandl, M. (2006) Drug permeability across a phospholipid vesicle-based barrier. European Journal of Pharmaceutical Sciences, 28, 336-343.
58. Flaten, G.E., Dhanikula, A.B., Luthman, K. and Brandl, M. (2006) Drug permeability across a phospholipid vesicle based barrier:Anovel approach for studying passive diffusion. European Journal of Pharmaceutical Sciences, 27, 80-90.
59. Flaten, G.E., Luthman, K., Vasskog, T. and Brandl, M. (2008) Drug permeability across a phospholipid vesicle-based barrier. European Journal of Pharmaceutical Sciences, 34, 173-180.
60. Flaten, G.E., Skar, M., Luthman, K. and Brandl, M. (2007) Drug permeability across a phospholipid vesicle based barrier: 3. Characterization of drugmembrane interactions and the, effect of agitation on the barrier integrity and on the permeability. European Journal of Pharmaceutical Sciences, 30, 324-332.
61. Corti, G., Maestrelli, F., Cirri, M., Furlanetto, S. and Mura, P. (2006) Development and evaluation of an in vitro method for prediction of human drug absorption. European Journal of Pharmaceutical Sciences, 27, 346-353.
62. Corti, G., Maestrelli, F., Cirri, M., Zerrouk, N. and Mura, P. (2006) Development and evaluation of an in vitro method for prediction of human drug absorption. European Journal of Pharmaceutical Sciences, 27, 354-362.
63. Chen, X., Murawski, A., Patel, K., Crespi, C.L. and Balimane, P.V. (2008) A novel design of artificial membrane for improving the parallel artificial membrane permeability assay model. Pharmaceutical Research, 25, 1511-1520.
64. Sugano, K. and Sakai, K. (2004) Mucopolysaccharide-layered lipid membrane, membrane permeabilitymeasuringfilter/ apparatus/kit,membrane permeability evaluation method, and test substance-screening method. Patents 31362, 2005221442, 20040206.
65. Sugano, K., Okazaki, A., Sugimoto, S., Tavornvipas, S., Omura, A. and Mano, T. (2007) Solubility and dissolution profile assessment in drug, discovery. DMPK, 22, 225-254.
66. Loftsson, T., Konradsdottir, F. and Masson, M. (2006) Development and evaluation of an artificial membrane for determination of drug availability. International Journal of Pharmaceutics, 326, 60-68.
67. Sugano, K., Hamada, H., Machida, M., Ushio, H., Saitoh, K. and Terada, K. (2001) Optimized conditions of bio-mimetic artificial membrane permeation assay. International Journal of Pharmaceutics, 228, 181-188.
68. Bendels, S., Tsinman, O., Wagner, B., Lipp, D.,Parrilla, I., Kansy, M. andAvdeef, A. (2006) PAMPA-excipient classification gradient map. Pharmaceutical Research, 23, 2525-2535.
69. Li, C., Nair, L., Liu, T., Li, F., Pichardo, J., Agrawal, S., Chase, R., Tong, X., Uss, A.S., Bogen, S., Njoroge, F.G., Morrison, R.A. and Cheng, K.C. (2008) Correlation between PAMPA permeability and cellular activities of hepatitis C virus protease inhibitors. Biochemical Pharmacology, 75, 1186-1197.
70. Balimane, P.V. and Chong, S. (2005) Cell culture-based models for intestinal permeability: A critique. Drug Discovery Today, 10, 335-343.
71. Youdim, K.A., Avdeef, A. and Abbott, N.J. (2003) In vitro trans-monolayer permeability calculations: often forgotten assumptions. Drug Discovery Today, 8, 997-1003.
72. Fujikawa, M., Nakao, K., Shimizu, R. and Akamatsu, M. (2007) QSAR study on permeability of hydrophobic compounds with artificial membranes. Bioorganic & Medicinal Chemistry, 15, 3756-3767.
73. Kansy, M., Fischer, H., Kratzat, K., Senner, F., Wagner, B. and Parrilla, I. (2001) High-throughput artifical membrane permeability studies in early lead discovery and development, in Pharmacokinetic Optimization in Drug Research, 3-906390-22-5. ed. (eds B. Testa, H. van de Waterbeemd, G. Folkers and R. Guy), Wiley-VCH, Zurich, pp. 447-464.
74. Krishna, G., Chen, K.-j., Lin, C.-c. and Nomeir, A.A. (2001) Permeability of lipophilic compounds in drug discovery using in-vitro human absorption model, Caco-2. International Journal of Pharmaceutics, 222, 77-89.
75. Yamashita, S., Tanaka, Y., Endoh, Y., Taki, Y., Sakane, T., Nadai, T. and Sezaki, H. (1997) Analysis of drug permeation across Caco-2. monolayer: implication for predicting in vivo drug absorption. Pharmaceutical Research, 14, 486-491.
76. Saitoh, R., Sugano, K., Takata, N., Tachibana, T., Higashida, A., Nabuchi, Y. and Aso, Y. (2004) Correction of permeability with pore radius of tight junctions in Caco-2. monolayers improves the prediction of the dose fraction of hydrophilic drugs absorbed by humans. Pharmaceutical Research, 21, 749.
77. Sugano, K., Nabuchi, Y., Machida, M. and Aso, Y. (2003) Prediction of human intestinal permeability using artificial membrane permeability. International Journal of Pharmaceutics, 257, 245-251.
78. Sugano, K., Takata, N., Machida, M., Saitoh, K. and Terada, K. (2002) Prediction of passive intestinal absorption using bio-mimetic artificial membrane permeation assay and the paracellular pathway model. International Journal of Pharmaceutics, 241, 241-251.
79. Volpe Donna, A. (2008) Variability in Caco-2. and MDCK cell-based intestinal permeability assays. Journal of Pharmaceutical Sciences, 97, 712-725.
80. Ekins, S., Mestres, J. and Testa, B. (2007) In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling. British Journal of Pharmacology, 152, 9-20.
81. Ruiz, G.A., Bermejo, M., Moss, A. and Casabo, V.G. (2008) Pharmacokinetics in drug discovery. Journal of Pharmaceutical Sciences, 97, 654-690.
82. Camenisch, G., Folkers, G. and van de Waterbeemd, H. (1996) Review of theoretical passive drug absorption models: historical background, recent developments and limitations. Pharmaceutica Acta Helvetiae, 71, 309-327.
83. Sugano, K., Obata, K., Saitoh, R., Higashida, A. and Hamada, H. (2006) Processing of biopharmaceutical profiling data in drug discovery, in Pharmacokinetic Profiling in Drug Research (eds B. Testa, S. Kramer, H. Wunderli-Allenspach and G. Folkers), Wiley-VCH, Zurich, pp. 441-458.
84. Obata, K., Sugano, K., Saitoh, R., Higashida, A., Nabuchi, Y., Machida, M. and Aso, Y. (2005) Prediction of oral drug absorption in humans by theoretical passive absorption model. International Journal of Pharmaceutics, 293, 183-192.
85. Liu, Y. and Hunt, C.A. (2005) Studies of intestinal drug transport using an in silico epithelio-mimetic device. BioSystems, 82, 154-167.
86. Liu, Y. andHunt, C.A. (2006)Mechanistic study of the cellular interplay of transport and metabolism using the synthetic modeling method. Pharmaceutical Research, 23, 493-505.
87. Garmire, L.X. and Hunt, C.A. (2008) In silico methods for unraveling the mechanistic complexities of intestinal absorption: metabolism-efflux transport interactions. Drug Metabolism and Disposition.
88. Garmire, L.X., Garmire, D.G. and Hunt, C.A. (2007) An in silico transwell device for the study of drug transport and drug-drug interactions. Pharmaceutical Research, 24, 2171-2186.
89. Willmann, S., Lippert, J. and Schmitt, W. (2005) From physicochemistry to absorption and distribution: predictive mechanistic modelling and computational tools. Expert Opinion on Drug Metabolism and Toxicology, 1, 159-168.
90. Tubic, M., Wagner, D., Spahn, L.H., Bolger, M.B. and Langguth, P. (2006) In silico modeling of non-linear drug absorption for the P-gp substrate talinolol and of consequences for the resulting pharmacodynamic effect. Pharmaceutical Research, 23, 1712-1720.
91. Shaikh, S.A., Jain, T., Sandhu, G., Latha, N. and Jayaram, B. (2007) From drug target to leads-sketching a physicochemical pathway for lead molecule design in silico. Current Pharmaceutical Design, 13, 3454-3470.
92. Johnson, S.R. and Zheng, W. (2006) Recent progress in the computational prediction of aqueous solubility and absorption. AAPS Journal, 8, E27-E30.
93. Gola, J., Obrezanova, O., Champness, E. and Segall, M. (2006) ADMET property prediction: The state of the art and current challenges. QSAR and Combinatorial Science, 25, 1172-1180.
94. Hou, T., Wang, J., Zhang, W., Wang, W. and Xu, X. (2006) Recent advances in computational prediction of drug absorption and permeability in drug discovery. Current Medicinal Chemistry, 13, 2653-2667.
95. Palmer, A.M. and Stephenson, F.A. (2005) CNS drug discovery: challenges and solutions. Drug News & Perspectives, 18, 51-57.
96. Lemaire, M. and Desrayaud, S. (2005) The priorities/needs of the pharmaceutical industry in drug delivery to the brain. International Congress Series, 2005, 32-46.
97. Yoshihisa, S. (2008) Molecular design for enhancement of ocular penetration. Journal of Pharmaceutical Sciences, 97, 2462-2496.
98. Stoner, C.L., Troutman, M., Gao, H., Johnson, K., Stankovic, C., Brodfuehrer, J., Gifford, E. and Chang, M. (2006) Moving in silico screening into practice: A minimalist approach to guide permeability screening! Letters in Drug Design and Discovery, 3, 575-581.
99. Refsgaard, H.H.F., Jensen, B.F., Brockhoff, P.B., Padkjar, S.B., Guldbrandt, M. and Christensen, M.S. (2005) In silico prediction of membrane permeability from calculated molecular parameters. Journal of Medicinal Chemistry, 48, 805-811.
100. Zhang, L., Balimane, P.V., Johnson, S.R. and Chong, S. (2007) Development of an in silico model for predicting efflux substrates in Caco-2. cells. International Journal of Pharmaceutics, 343, 98-105.
101. Chang, C., Ekins, S., Bahadduri, P. and Swaan, P.W. (2006) Pharmacophorebased discovery of ligands for drug transporters. Advanced Drug Delivery Reviews, 58, 1431-1450.
102. van, Z.J.J., Wortelboer, H.M., Bijlsma, S., Punt, A., Usta, M., Bladeren, P.J.v., Rietjens, I.M.C.M. and Cnubben, N.H.P. (2005) Quantitative structure activity relationship studies on the flavonoid mediated inhibition of multidrug resistance proteins 1. and 2. Biochemical Pharmacology, 69, 699-708.
103. Zhang, S., Yang, X., Coburn, R.A. and Morris, M.E. (2005) Structure activity relationships and quantitative structure activity relationships for the flavonoidmediated inhibition of breast cancer resistance protein. Biochemical Pharmacology, 70, 627-639.
104. Kamphorst, J., Cucurull-Sanchez, L. and Jones, B. (2007)Aperformance evaluation of multiple classification models of human PEPT1. inhibitors and noninhibitors. QSAR& Combinatorial Science, 26, 220-226.
105. Biegel, A., Gebauer, S., Hartrodt, B., Brandsch, M., Neubert, K. and Thondorf, I. (2005) Three-dimensional quantitative structure-activity relationship analyses of beta-lactam antibiotics and tripeptides as substrates of the mammalian H+/peptide cotransporter PEPT1. Journal ofMedicinal Chemistry, 48, 4410-4419.
106. Biegel, A., Gebauer, S., Brandsch, M., Neubert, K. and Thondorf, I. (2006) Structural requirements for the substrates of the H+/peptide cotransporter PEPT2. determined by three-dimensional quantitative structureactivity relationship analysis. Journal of Medicinal Chemistry, 49, 4286-4296.
107. Adson, A., Ruab, T.J., Burton, P.S., Barsuhn, C.L., Hilgers, A.R., Audus, K.L. and Ho, N.F.H. (1994) Quantitative approaches to delineate paracellular diffusion in cultured epithelial cell monolayers. Journal of Pharmaceutical Sciences, 83, 1529-1530.
108. Fujikawa, M., Ano, R., Nakao, K., Shimizu, R. and Akamatsu, M. (2005) Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: application to prediction of Caco-2. cell permeability. Bioorganic and Medicinal Chemistry, 13, 4721-4732.
109. Verma, R.P., Hansch, C. and Selassie, C.D. (2007) Comparative QSAR studies on PAMPA/modified PAMPA for high throughput profiling of drug absorption potential with respect to Caco-2. cells and human intestinal absorption. Journal of Computer-Aided Molecular Design, 21, 3-22.
110. Kalyanaraman, C. and Jacobson, M.P. (2007) An atomistic model of passive membrane permeability: application to a series of FDA approved drugs. Journal of Computer-Aided Molecular Design, 21, 675-679.
111. Zhang, X., Shedden, K. and Rosania, G.R. (2006) A cell-based molecular transport simulator for pharmacokinetic prediction and cheminformatic exploration. Molecular Pharmaceutics, 3, 704-716.
112. Sugano, K., Obata, K., Saitoh, R., Higashida, A. and Hamada, H. (2006) Processing of Biopharmaceutical Profiling Data in Drug Discovery, Wiley-VCH, Zurich, pp. 441-458.